secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001193125-24-081562
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Interim CFO Drexler resigns; Garner appointed PFO/PAO, will depart May 15, 2024
-------------------------------------------------------------------------------

- Susan L. Drexler resigned as Interim CFO, PFO and PAO effective March 25, 2024; remains consultant via Danforth Advisors.
- Charles Garner appointed as principal financial officer and principal accounting officer effective March 25, 2024.
- Garner's employment ends May 15, 2024; he will receive 12 months base salary severance if not terminated for cause or he quits without good reason before then.
- Garner previously SVP Finance since Oct 2023, former CFO of Lung Therapeutics (acquired by Aileron).
- No permanent CFO replacement announced; leadership transition in finance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/0001193125-24-081562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/d800276d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-081562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer